Other · developed by Janux Therapeutics
JANX013 is an agent administered intravenously. It is studied in metastatic castration-resistant prostate cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07813637 | Phase 1 | Prostate Cancer | Recruiting | JANX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Castration-Resistant Prostate Cancer (CRPC)Metastatic Castration-Resistant Prostate Cancer PatientsMetastatic Prostate CancerProstate Cancer
Updated Oct 18, 2026. Something wrong or missing? Report it on the JANX page.
See JANX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
JANX catalysts and pipeline →